Contact:

David K. Waldman/John W. Heilshorn	The Quigley Corporation
Lippert Heilshorn & Associates	Carl Fonash
(212) 838-3777	Shareholder Relations
dwaldman@lhai.com	(267) 880-1111

DOYLESTOWN, PA. - November 5, 2004 - The Quigley Corporation (Nasdaq: QGLY) In response to news reports citing a lawsuit filed in Bucks County, PA, yesterday by eight consumers who are taking legal action against The Quigley Corporation, manufacturers of its zinc gluconate nasal spray, company officials said they had no knowledge of the lawsuit until a faxed complaint was received at 2:15 PM EST on November 5, 2004. The company has yet to be officially served and upon a cursory look at the faxed documents, the company considers the suit to be frivolous and without merit and will defend it vigorously. The company reaffirmed the safety of its Nasal Spray due to completion of clinical safety studies conducted prior to retail introduction in September of 2003.

"Quigley conducts thorough clinical trials on all its products before introducing them to the marketplace. Accordingly, we conducted a double-blind, placebo-controlled study to evaluate the safety of the nasal spray. Subjects receiving three days of treatment with intranasal zinc did not demonstrate a diminished sense of smell," said Guy Quigley, president and CEO of The Quigley Corporation.

Any nasal product, including saline spray, might cause a person to experience irritation. Additionally, consumers may incorrectly attribute a nasal spray for the onset of a symptom, which should instead be attributed to a pre-existing condition, such as a sinus infection. The list of conditions that have been documented to cause a loss of smell is extensive, with the most common being head injury, upper respiratory infection and nasal and sinus disease.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the COLD-EEZE® family of patented Zinc Gluconate Glycine (ZIGG™) lozenges, gums, sugar free tablets and nasal spray. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com.

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.